T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the United States Department of Homeland Security, has awarded the company a contract. The Department of Health and Human Services is contributing an additional $3.7 million to the multi-year cost-sharing agreement between BARDA and T2 Biosystems. If all contract options are exercised, the total potential BARDA financing is $62.0 million, representing a reduction in the scope of work under contract option 3.

The additional funds will be utilized to progress the T2Resistance® Panel and T2Biothreat® Panel clinical trials in the United States, as well as to make submissions to the U.S. Food and Drug Administration. FDA for regulatory approval in the United States.